185 related articles for article (PubMed ID: 26191643)
1. Using Therapeutic Drug Monitoring to Identify Variable Infliximab Metabolism in an Individual Patient With Ulcerative Colitis.
Stein BN; Pellish RS; Thompson KD; Baptista V; Siegel CA
J Clin Gastroenterol; 2016 Jan; 50(1):66-8. PubMed ID: 26191643
[TBL] [Abstract][Full Text] [Related]
2. Optimising infliximab induction dosing for patients with ulcerative colitis.
Dreesen E; Faelens R; Van Assche G; Ferrante M; Vermeire S; Gils A; Bouillon T
Br J Clin Pharmacol; 2019 Apr; 85(4):782-795. PubMed ID: 30634202
[TBL] [Abstract][Full Text] [Related]
3. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
4. A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients.
Pérez-Pitarch A; Ferriols-Lisart R; Alós-Almiñana M; Mínguez-Pérez M
Rev Esp Enferm Dig; 2015 Mar; 107(3):137-42. PubMed ID: 25733037
[TBL] [Abstract][Full Text] [Related]
5. Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
Wong U; Cross RK
Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1039-1046. PubMed ID: 28876147
[TBL] [Abstract][Full Text] [Related]
6. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience.
Dave MB; Dherai AJ; Desai DC; Mould DR; Ashavaid TF
Eur J Clin Pharmacol; 2021 Jan; 77(1):55-62. PubMed ID: 32803288
[TBL] [Abstract][Full Text] [Related]
7. New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases.
Nemoz B; Ternant D; Bailly S; Gautier-Veyret E; Jourdil JF; Bonaz B; Stanke-Labesque F
Br J Clin Pharmacol; 2019 Apr; 85(4):722-728. PubMed ID: 30575085
[TBL] [Abstract][Full Text] [Related]
8. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
[TBL] [Abstract][Full Text] [Related]
9. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
[TBL] [Abstract][Full Text] [Related]
10. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients.
Dubinsky MC; Phan BL; Singh N; Rabizadeh S; Mould DR
AAPS J; 2017 Jan; 19(1):215-222. PubMed ID: 27739008
[TBL] [Abstract][Full Text] [Related]
12. Infliximab Maintenance Dosing in Inflammatory Bowel Disease: an Example for In Silico Assessment of Adaptive Dosing Strategies.
Wojciechowski J; Upton RN; Mould DR; Wiese MD; Foster DJR
AAPS J; 2017 Jul; 19(4):1136-1147. PubMed ID: 28444562
[TBL] [Abstract][Full Text] [Related]
13. Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.
Selinger CP; Lenti MV; Clark T; Rafferty H; Gracie D; Ford AC; OʼConnor A; Ahmad T; Hamlin PJ
Inflamm Bowel Dis; 2017 Dec; 23(12):2083-2088. PubMed ID: 29140939
[TBL] [Abstract][Full Text] [Related]
14. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab.
Papamichael K; Chachu KA; Vajravelu RK; Vaughn BP; Ni J; Osterman MT; Cheifetz AS
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1580-1588.e3. PubMed ID: 28365486
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study.
Jahnsen J; Detlie TE; Vatn S; Ricanek P
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():45-52. PubMed ID: 26395534
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic drug monitoring in inflammatory bowel disease.
Jossen J; Dubinsky M
Curr Opin Pediatr; 2016 Oct; 28(5):620-5. PubMed ID: 27583410
[TBL] [Abstract][Full Text] [Related]
18. Changes in cytokine profile may predict therapeutic efficacy of infliximab in patients with ulcerative colitis.
Sato S; Chiba T; Nakamura S; Matsumoto T
J Gastroenterol Hepatol; 2015 Oct; 30(10):1467-72. PubMed ID: 25968585
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Use in a Child With Ulcerative Colitis and Prior In Utero Exposure to Infliximab.
Lim J; Hammami MB; Mahadevan U
Gastroenterology; 2020 May; 158(6):1834-1835. PubMed ID: 31926172
[No Abstract] [Full Text] [Related]
20. [Usefulness of therapeutic monitoring of infliximab in the treatment of inflammatory bowel disease].
Quera R; Moreno M; Simian D; Ibáñez P; Lubascher J; Figueroa C; Flores L; Kronberg U; Pizarro G; Fluxá D
Rev Med Chil; 2018 Nov; 146(11):1241-1251. PubMed ID: 30725037
[No Abstract] [Full Text] [Related]
[Next] [New Search]
